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Original Article

Efficacy of Liraglutide in clinical practice:
Single centre experience
Muhammad Owais Rashid1, Sumerah Jabeen2,
Adeel Khoja3, Najmul Islam4
ABSTRACT
Background and Objective: GLP-one receptor agonists are amongst the unique antidiabetes medications
that have significant metabolic and cardiovascular benefits in addition to glucose lowering effect. To best
of our knowledge, there is no published data on efficacy of liraglutide use among Pakistani population.Our
objective was to ascertain the efficacy of liraglutide use among type two diabetes patients.
Methods: This retrospective study was conducted at the Endocrinology Clinics of Aga Khan University
Hospital (AKUH) Karachi, Pakistan during the period from July 01, 2016 to 30th June, 2017. Liraglutide
was prescribed to 68 obese type two diabetes patients with uncontrolled diabetes taking more than one
oral medication ± insulin. Starting dose of Liraglutide was 0.6 mg, which was increased to 1.2 mg after 1-2
weeks with further increment to 1.8 mg/day based on tolerance and individual patient preference. Dose
of other diabetes medications was adjusted according to clinical judgment whereas Dipeptidyl peptidase4(DPP-4) inhibitors were discontinued.
Results: Mean age of cohort was 55 years (SD=10.94 years) with median body mass index of 36.45 kg/m2
and majority(57.35%) were on a dose of 1.2 mg of Liraglutide per day. Median HbA1c reduced to 7.50% and
7.40% at three months and six months respectively vs 8.45% at baseline. Mean reduction in weight after
three month was two kilograms and at six months, it was 1.38 kilograms respectively.
Conclusion: Liraglutide as add on therapy demonstrated favourable HbA1c and weight reduction in obese
uncontrolled type two Diabetes Pakistani subjects.
KEYWORDS: Glucagon like peptide-1(GLP-1) agonist, Liraglutide, Type 2 diabetes.
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INTRODUCTION
Type 2 diabetes being a complex metabolic
disorder remains an ever-increasing global health
care issue. While glycemic control is associated
with reductions in the risk of micro vascular
complications, the macro vascular benefits of
glycemic control are not very clear.1 The reason
might be that the benefits of improved glycemic
control take a long time to influence the progression
of atherosclerotic vascular disease.
There are multiple treatment options available
for patients with diabetes, many of which are
either weight neutral, cause weight gain or
promote weight loss. One of the disadvantage of
having these multiple treatment options is that,
the wide range of options may cause problem for
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the health care provider to prescribe the optimal
regimen. In making these decisions, the prescriber
should consider patient’s disease progression,
comorbidities, and concomitant treatment.2
After decades of disappointment in attempting
to control cardiovascular disease progression in
type 2 diabetes with careful glycemic control,a
new found hope that newer drugs, particularly
the Glucagon like peptide 1 receptor (GLP-1)
agonist and the sodium glucose co transporter 2
SGLT-2 inhibitors have cardiovascular benefits
independent of glycemic control has led to a new
dimension in the management of type 2 diabetes.3
Despite its role in glucose homeostasis, the
GLP-1 receptor is amazingly widely distributed
throughout the body, including heart. GLP1 may exert its effects through both receptordependent and receptor-independent mechanism
and through the actions of both the intact peptide
and its metabolites.4 Injectable GLP-1 receptor
agonist mimics endogenous GLP-1 by stimulating
pancreatic insulin secretion. They have beneficial
nonglycemic metabolic effects, notably the
potential for weight loss.5
Liraglutide a long acting GLP-1 receptor
agonist has been approved for the treatment of
type 2 diabetes.6 To assess the long-term effects
of liraglutide on cardiovascular outcomes and
other clinically important events, the Liraglutide
Effect and Action in Diabetes: Evaluation of
Cardiovascular Outcome Results (LEADER)
trial was initiated in 2010.1 In the LEADER’s
trial, 9340 patients with type 2 diabetes at high
cardiovascular risk were randomized to receive
the longer-acting drug liraglutide 1.8 mg (or
maximum tolerated dose) or matching placebo
once daily and followed for a mean of 3.5 years.
There was a 23% statistically significant (p-value=
0.001 for non-inferiority, p-value=0.01 for
superiority) reduction in the primary end point,
including a 22% reduction in cardiovascular
mortality (p-value=0.007) and 15% reduction in
total mortality (p-value=0.02).3 Gastrointestinal
adverse effects were more common in the
patients randomized to liraglutide, the trial
concluded that the patients in liraglutide group
had significantly reduced risk of cardiovascular
events and they had better micro vascular
outcomes then the group with standard therapy.1
A few studies have been conducted on South
Asian population in India and all of these studies
concluded that, liraglutide significantly improves
glycemic control with low risk of hypoglycemia
Pak J Med Sci
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and is associated with significant weight loss in
Indian patients with type 2 diabetes mellitus.7 To
best of our knowledge, there is no published data
on efficacy of liraglutide use among Pakistani
population.
Hence, this study aimed to assess the efficacy of
liraglutide in terms of glycemic control and weight
reduction in type 2 diabetes patients Pakistani
population during routine clinical practice at
outpatient clinic.
METHODS
This retrospective study was conducted at the
Endocrinology Clinics of Aga Khan University
Hospital (AKUH) Karachi, Pakistan during the
period from July 01, 2016 to 30th June, 2017. This
study was approved by the ethical committee
(Ref. No. 4911-Med-ERC-17) of the Aga Khan
University.
Liraglutide was prescribed to 68 obese (BMI
>23kg/m2) type 2 diabetes patients with
uncontrolled diabetes (HbA1C>7%). All patients
were on more than one oral hypoglycemic agents
with or without insulin. DPP4 inhibitors were
stopped if patients were on it whereas other
antidiabetes medication were adjusted according to
clinical judgment. All patients were advised to start
0.6 mg/day of liraglutide. An increment in dose up
to 1.2 mg/day was done after 1-2 weeks which was
later increased to 1.8 mg/day based on tolerance
and individual patient preference.
Patients aged below 16 years, non diabetics,
having type 1 diabetes, not taking liraglutide were
excluded from the study. Informed written consent
was obtained from hospital authorities to use the
data of patients. No personal detail by any means
related to any patient was revealed in regard of
ethical considerations.
Data of patients taking liraglutide was retrieved
from hospital medical record maintained by
Health Information Management System of
Aga Khan University Hospital after acquiring
permission. Data collection was done by means
of a data collection tool specifically designed
for the study, keeping in mind the indicators/
variables asked from the diabetes patient at the
time of initial and follow-up visits in the diabetes
clinic. A research assistant was trained to review
the files of all the diabetes patients falling under
the aforementioned timelines by means of a
data collection tool. Data collection tool mainly
covered information on demographic details of
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Graphical Representation of all
Continuous Variables in the Dataset.

Histograms: AGE Distribution
Check: Symmetrically Distributed.

WEIGHT: Distribution Check: Symmetrically Distributed.

the patient, duration of diabetes and patients with
history of Hypertension (taking anti hypertensive
medication or BP>140/90mmhg on home BP
monitoring), Dyslipidemia (serum LDL>100 mg/
dl, triglycerides >150mg/dl), Coronary artery
disease including history of unstable angina,
previous history of
Myocardial infarction
or coronary angioplasty, retinopathy (both
proliferative and non proliferative) diagnosed
and treated by ophthalmologist, neuropathy
(diagnosed on previous visits with compromised
vibration and pin prick sensation assessed with
a calibrated tuning fork and 10gm monofilament
testing) and nephropathy (confirmed by presence
of albuminuria in urine on 2 or more occasions),
medication details, changes in glycosylated
haemoglobin(HbA1C) and weight, any reported
side effects of liraglutide and history of
discontinuation if any.
Plan of Analysis: Frequencies with percentages
were reported for categorical variables for e.g.
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BODY MASS INDEX (BMI): Distribution
Check: Asymmetrically Distributed.

HBA1C BEFORE STARTING LIRAGLUTIDE:
Distribution Check: Asymmetrical Distribution.

gender, associated comorbids, and associated
Diabetes complications, medication history before
adding liraglutide, side effects of Liraglutide
etc. Mean with standard deviation was reported
for all symmetrically distributed continuous
variables while median with inter quartile range
was reported for all asymmetrically distributed
variables for e.g. age, duration of comorbids,
baseline anthropometric measurements such
as height, weight, BMI, BP, Pulse, HbA1C and
subsequent followup measurements at three and
six months, etc. All the analysis was performed on
STATA version 12.
RESULTS
Of the total 68 patients studied, mean age of
cohort was 55 years (SD=10.94 years). Among
them 50% were male, having a median diabetes
duration of 13 years. More than four-fifth of
our study population had dyslipidemia and
hypertension and less than 15% had coronary
Vol. 36 No. 3
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Table-I: Descriptive analysis of patients on liraglutide.
S. Variables
No.
1
2

3
4
5
6
7
8
9
10
11

12
13
14
15
16
17
18
19

n = 68 (%)

Age*
54.47 ± 10.94
Gender
(a) Male
34 (50%)
(b) Female
34 (50%)
Duration of Diabetes*
13 ( 7 – 19)
Presence of Dyslipidemia
57 (83.82%)
Presence of Hypertension
61 (89.71%)
Presence of Coronary
9 (13.24%)
Artery Disease
Presence of Retinopathy
4 (5.90%)
Presence of Neuropathy
5 (7.35%)
Presence of Nephropathy
3 (4.41%)
Body Mass Index (kg/m2)*
36.45 (32.40–41.9)
Dose of Liraglutide (mg)
(a) 0.6
7 (10.29%)
(b) 1.2
39 (57.35%)
(c) 1.8
22 (32.35%)
Participants on Sulfonylurea
30 (44.12%)
before liraglutide
Participants on Metformin
64 (94.12%)
before liraglutide
Participants on Thiazolidinedione
4 (5.88%)
before liraglutide
Participants on DDP-4 inhibitors
33 (48.53%)
before liraglutide
Participants on Basal Insulin
22 (30.88%)
before liraglutide
Participants on Pre-Mixed Insulin
19 (27.94%)
before liraglutide
Participants on Basal Bolus
22 (32.35%)
Regimen before liraglutide
Creatinine levels of participants *
0.8 (0.7 – 0.95)

artery disease (Table-I). Median body mass index
of our study participants was 36.45 kg/m2, and
majority of them (57.35%) were on a dose of 1.2
mg of Liraglutide per day. Study participants were
mostly on maximum doses of sulfonylureas (44%),
metformin (94%), DPP-4 inhibitors (49%), basal
insulin (31%), pre-mixed insulin (28%), basal bolus
regimen (32%) either alone or in combination before
addition of Liraglutide to the treatment regimen.
DPP-4 inhibitors were discontinued in all patients
once liraglutide was introduced and dosage of
other antidiabetes medications adjusted. Median
HbA1c at baseline was 8.45% and it reduced to
7.50% and 7.40% at three months and six months
post-Liraglutide respectively. The mean reduction
in weight after three months of Liraglutide was 2
Pak J Med Sci
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kilograms and at six months, it was 1.38 kilograms
respectively. There was no significant difference
noted in the systolic and diastolic blood pressures
and the pulse rate at three and six months from the
baseline, respectively (Table-I).
Side-effects reported after the start of
Liraglutide were mainly nausea (9%), vomiting
(6%), diarrhoea (7%) and others (12%) which
included headache, dizziness and constipation.
In addition to this, Liraglutide was discontinued
due to the side effects and cost in about seven
participants (10%) of our study cohort and
therefore they were not included in the final
analysis.
DISCUSSION
This small scale study verifies that Liraglutide as
an add on therapy was beneficial for both HbA1c
and weight reduction in Pakistani subjects with
Diabetes Mellitus (T2DM). The HbA1c reduction
at 3 months from baseline in our study was 0.95%
and 1.05% at 6 months. There was -2.00 ± 3.10 kg
weight reduction at three months and -1.38 ± 3.27
kg at 6 months. The HbA1c reduction in our study
corresponds to the maximum HbA1c reduction
noted in LEAD -4 trial which showed 1.5 %
reduction at 1.2 and 1.8 mg of Liraglutide doses
at 24 weeks of treatment.8 Although the mean
weight reduction in our study noted at six months
of treatment was less as anticipated but it was
comparable to weight reduction in LEAD trials
which was also less than 3 kg with the exception
of LEAD-6 which showed a weight reduction of
3.24 kg.9 The probable explanation to this could be
that weight loss demonstrated with Liraglutide is
dose dependant whereas in our study more than
50% subjects were on 1.2mg doses.10-12 No change
in systolic, diastolic blood pressures and pulse
at baselines and at six months post treatment
from the baseline was noted although this was
not the primary objective and includes several
confounding factors like retrospective design,
medication adherence, operator variability etc.
Gastrointestinal side effects were the commonly
reported adverse effects among the study
participants and seven participants withdrew
liraglutide owing to these side effects. Financial
constraints remained an important factor in
continuing patients on Liraglutide therapy.
Following the LEADER trial which showed
significant reduction in the composite outcome
of the first occurrence of death from CV causes,
Vol. 36 No. 3
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Table-II: Comparison of variables from baseline following Liraglutide treatment.
S. Variables
No.
1
2
3
4
5
6

7

At Baseline

At 3 months

At 6 months

HbA1c (at baseline) of participant (%)*
8.45 (7.55-9.45) 7.50 (6.70-8.6) 7.40 (6.70-7.90)
Change in weight after three months
-2.00±3.10
-1.38±3.27
post-Liraglutide of participants*
Systolic Blood Pressure (at baseline) of participants (mmHg)*
138.28±17.11 134.95±23.60
138.07±15.60
Diastolic Blood Pressure (at baseline) of participants (mmHg)*
74.42±10.05
72.93±8.80
72.64±11.70
Pulse Rate (at baseline) of participants (beats/min)*
89.34±13.50
90.40±14.85
92.14±16.61
Side Effects reported by participants post-Liraglutide$:
1. Nausea		
6 (8.82%)
2. Vomiting		
4 (5.88%)
3. Diarrhea		
5 (7.35%)
4. Others		
8 (11.76%)
Liraglutide discontinued due to side effects & cost		
7 (10.29%)

Legends used in Table-I & II: * All the continuous variables in the table above have been reported as either mean with
standard deviation (Mean±SD), if they are symmetrically distributed or as median with interquartile range (Median
(25th percentile – 75th percentile) if they are asymmetrically distributed.
$ It was a multiple response question and the sum of the percentages will not be equal to 100.

non-fatal myocardial infarction or nonfatal stroke
in T2DM subjects with high CV risk, Liraglutide
along with other GLP 1 agonists is now
considered as second line therapy in high risk
CV patients. The EASD and the ADA updated
2018 consensus statement for DM management
in patients with T2 DM encourages use of GLP 1
receptor agonist and SGLT2 inhibitor for patients
with clinical cardiovascular disease as an add on
therapy after metformin.13 The exact mechanism
influencing the beneficial effects of Liraglutide
on cardiovascular benefit and weight reduction
remains unknown but one probable hypotheses
is reduction in visceral fat, hepatic steatosis and
systemic inflammation which are considered
strong contributors for cardiovascular morbidity
in patients with diabetes.14,15 Bouchi et al.
demonstrated the Liraglutide efficacy in reducing
visceral fat and thus ameliorating hepatic
steatosis, albuminuria and microinflammation in
T2DM patients along with improved quality of
life following treatment.16
This single centre retrospective study is the
first Pakistani study in evaluating the liraglutide
efficacy in T2 Diabetes Pakistani subjects. The
mean duration of diabetes in our study population
was 13 years but nevertheless there was a mean
reduction in HbA1c at both three months and
six months. Kaur et al. in their Liraglutide trial
highlighted that weight reduction and diabetes
control was irrespective of the duration of
diabetes and baseline HbA1c thus concluding
Pak J Med Sci
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that liraglutide effectiveness could be achieved
in patients with long standing diabetes as well.17
Although favourable HbA1C and weight reduction
was found at six months post liraglutide several
confounding factors like diet and physical activity
could not be controlled due to retrospective design
of study.
Despite the effective HbA1c and weight reduction
Liraglutide remains an expensive treatment
option for a country like Pakistan where majority
of the patients do not have medical insurance.
Since this is a single centre experience, prospective
studies are required evaluating multiple beneficial
effects of liraglutide in patients with CV risks and
baseline albuminuria thus evaluating the new
cardio protective and renal protective role of this
drug.
CONCLUSION
Liraglutide as add on therapy demonstrated
favourable HbA1c and weight reduction in a real
life clinical setting of Pakistani Type-2 diabetes
patients. Despite the efficacy, financial constraints
remain an important set back in utilizing the
maximum benefitting effects of this drug.
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